CHIEF EDITOR
Claudia C. Dobler has no potential conflicts of interest to disclose.
EDITORIAL BOARD
ERS Education Council, ERS Assembly Secretaries
Daiana Stoltz has received fees for consultancy from Roche AG, Novartis AG, Astra-Zeneca AG, GSK AG, and Curetis AG; grants/grants pending from Astra-Zeneca AG, Pan Gas AG, Weimann AG, Curetis AG, and Boston-Scientific AG; and payment for lectures including service on speakers’ bureaus from Novartis AG.
Ioannis Vogiatzis has received grants from Philips Respironics.
Leo M.A. Heunks has received personal fees from Getinge; and grants from Orion Pharma and from Vent Free.
Catherine Greene has received grants from the Cystic Fibrosis Foundation Therapeutics, from Horizon2020 and from the Irish Research Council.
Pierantonio Laveneziana has received personal fees from Novartis France and from Boehringer France.
Omar Usmani has received fees for consultancy from Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, NAPP, Mundipharma, Sandoz, Cipla, Takeda, Zentiva, and Trudell Medical; grants/grants pending from Astra Zeneca, Boehringer Ingelheim, Chiesi, Prosonix, and Edmond Pharma; and payment for lectures including service on speakers’ bureaus from Boehringer Ingelheim, Chiesi, Cipla, NAPP, Mundipharma, Sandoz, and Aerocrine.
Charlotte Suppli Ulrik has no potential conflicts of interest to disclose.
Marielle Pijnenburg has no potential conflicts of interest to disclose.
Eva Polverino has received fees for consultancy for Bayer, Insmed, and Grifols; and speaker fees from Bayer, Grifols, Menarini, GSK, Pfizer, and Zambon.
Torsten Gerriet Blum has no potential conflicts of interest to disclose.
Anton Vonk Noordegraaf has received speakers’ fees from Actelion, MSD, Ferrer and Bayer in the past; in addition, he served on the scientific advisory board of Morphoghen.
Frans de Jongh has no potential conflicts of interest to disclose.
Stefano Aliberti has received grants and personal fees from Bayer Healthcare; and personal fees from AstraZeneca, Griffols, Aradigm Corporation, Basilea, Zambon, Novartis, Raptor, Chiesi, and Actavis UK Ltd.
Section Editors
Pierantonio Laveneziana has received personal fees from Novartis France and from Boehringer France.
Advisory Editors
Yochai Adir has no potential conflicts of interest to disclose.
Carol L. Armour has no potential conflicts of interest to disclose.
Frits M.E. Franssen has received personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Boehringer Ingelheim, and TEVA.
Georgia Hardavella has no potential conflicts of interest to disclose.
Georgia Narsavage has no potential conflicts of interest to disclose.
Athanasia Pataka has no potential conflicts of interest to disclose.
Renata Riha has no potential conflicts of interest to disclose.
Silke Ryan has no potential conflicts of interest to disclose.
Sophia Schiza has no potential conflicts of interest to disclose.
Michael E. Wilson has no potential conflicts of interest to disclose.
Early Career Members Committee representatives
Lieuwe D. Bos has received grants from the Dutch lung foundation (Young investigator grant), the Dutch lung foundation (Public-Private Partnership grant), and the ERS (short-term fellowship); and personal fees from Bayer (for consultancy).
This page was updated on 29 October, 2018